iX Biopharma Ltd. (42C) AI Stock Analysis

• Market Cap: S$103.99M
• Dividend Yield: N/A
• Average Volume (3M): 19.06M
• Price to Earnings (P/E): ―
• Beta (1Y): -0.06
• Revenue Growth: 30.34%
• EPS Growth: 17.14%
• Country: SG
• Employees: 35
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 888,843,400
• 10 Day Avg. Volume: 14,642,109
• 30 Day Avg. Volume: 19,064,559
• PEG Ratio: 0.08
• Price to Book (P/B): 38.32
• Price to Sales (P/S): 1.80
• P/FCF Ratio: -3.53
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 48 Neutral
• Price Target: S$0.00 ▼(-100.00% Downside)

The overall stock score is primarily impacted by the company's weak financial performance, characterized by persistent losses, high leverage, and cash flow issues. While technical analysis indicates strong upward momentum, the overbought conditions suggest caution. The valuation is unattractive due to a negative P/E ratio and lack of dividend yield.

iX Biopharma Ltd. Business Overview & Revenue Model

Company Description

iX Biopharma Ltd. (42C) is a biopharmaceutical company based in Singapore that specializes in the development and commercialization of innovative therapeutics and drug delivery systems. The company primarily focuses on creating proprietary drug formulations that leverage its unique sublingual delivery technology, which enhances the bioavailability of various medications. iX Biopharma operates in the pharmaceutical sector and aims to address unmet medical needs in areas such as pain management, addiction, and other health conditions through its advanced product pipeline.

How the Company Makes Money

iX Biopharma generates revenue through the development and commercialization of its proprietary drug products, which include both prescription and over-the-counter medications. The company's revenue model includes direct sales of its products, licensing agreements, and partnerships with pharmaceutical companies for the distribution and marketing of its formulations. Additionally, iX Biopharma may receive milestone payments and royalties from collaborations that leverage its drug delivery technology. Key partnerships with industry players and continuous investment in research and development contribute significantly to its revenue streams.

iX Biopharma Ltd. Financial Statement Overview

Summary

iX Biopharma Ltd. faces significant financial challenges across all verticals. The income statement shows persistent losses and weak margins, while the balance sheet reflects high leverage and poor equity returns. Cash flow issues further exacerbate the company's financial instability, highlighting the need for strategic improvements to enhance financial health and sustainability.

Income Statement

The income statement reveals significant challenges, with consistent negative net income and declining EBIT and EBITDA margins. Despite a slight revenue growth of 5.19% in the latest year, the company struggles with profitability, as evidenced by a negative net profit margin of -130.57%. The gross profit margin improved to 26.26%, but overall, the financial health remains weak.

Balance Sheet

The balance sheet indicates high leverage, with a debt-to-equity ratio of 16.17, suggesting significant financial risk. The return on equity is negative at -27.78%, reflecting poor returns for shareholders. The equity ratio is low, indicating a heavy reliance on debt financing, which could be risky if not managed properly.

Cash Flow

Cash flow analysis shows negative operating and free cash flows, with a concerning free cash flow growth rate of -18.61%. The operating cash flow to net income ratio is negative, indicating cash flow issues. The free cash flow to net income ratio is slightly positive at 1.05, but overall cash flow management appears weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.77M	7.77M	5.96M	5.91M	14.39M	1.75M
Gross Profit	2.04M	2.04M	1.05M	2.32M	12.29M	-382.00K
EBITDA	-5.87M	-8.96M	-8.68M	-8.51M	-2.84M	-10.79M
Net Income	-10.14M	-10.14M	-10.79M	-9.62M	-4.60M	-8.23M
Balance Sheet
Total Assets	11.28M	11.28M	14.62M	24.93M	28.52M	18.86M
Cash, Cash Equivalents and Short-Term Investments	866.00K	866.00K	1.77M	6.52M	13.49M	6.21M
Total Debt	5.90M	5.90M	5.20M	4.34M	4.41M	4.24M
Total Liabilities	10.92M	10.92M	10.28M	9.08M	8.77M	7.15M
Stockholders Equity	365.00K	365.00K	4.34M	15.85M	19.74M	11.71M
Cash Flow
Free Cash Flow	-3.96M	-3.96M	-6.84M	-8.36M	2.92M	-8.90M
Operating Cash Flow	-3.76M	-3.76M	-6.55M	-7.66M	3.12M	-8.35M
Investing Cash Flow	-201.00K	-201.00K	1.06M	-695.00K	-5.62M	-507.00K
Financing Cash Flow	3.12M	3.12M	724.00K	1.42M	9.79M	10.02M

iX Biopharma Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.08
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:42C, the sentiment is Positive. The current price of 0.08 is below the 20-day moving average (MA) of 0.09, above the 50-day MA of 0.05, and above the 200-day MA of 0.03, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 76.92 is Negative, neither overbought nor oversold. The STOCH value of 73.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SG:42C.

iX Biopharma Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
42C	―	S$103.99M	―	-431.07%	―	30.34%	17.14%

iX Biopharma Ltd. Corporate Events

iX Biopharma to Raise S$5 Million via Share Placement

iX Biopharma Ltd. has entered into a placement agreement with Oversea-Chinese Banking Corporation Limited to raise a minimum of S$5,000,000 through the issuance of new ordinary shares. This strategic move aims to enhance the company’s capital structure by offering shares that will constitute approximately 5.33% of its enlarged share capital. The placement is structured as an exempt offering in Singapore, targeting institutional and accredited investors, and is expected to bolster the company’s financial position, potentially impacting its market operations and investor relations positively.